Epizyme Inc (EPZM.OQ)
EPZM.OQ on NASDAQ Stock Exchange Global Select Market
10.55USD
17 Aug 2018
10.55USD
17 Aug 2018
Change (% chg)
$-0.20 (-1.86%)
$-0.20 (-1.86%)
Prev Close
$10.75
$10.75
Open
$10.70
$10.70
Day's High
$10.80
$10.80
Day's Low
$10.50
$10.50
Volume
66,338
66,338
Avg. Vol
94,364
94,364
52-wk High
$21.35
$21.35
52-wk Low
$8.62
$8.62
Select another date:
Tue, May 8 2018
BRIEF-Epizyme Reports Q1 Loss Per Share Of $0.49
* EPIZYME REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES
BRIEF-Epizyme Provides Update Regarding Tazemetostat Clinical Program
* EPIZYME PROVIDES UPDATE REGARDING TAZEMETOSTAT CLINICAL PROGRAM
BRIEF-Epizyme Inc Files For Potential Mixed Shelf, Size Not Disclosed
* EPIZYME INC FILES FOR POTENTIAL MIXED SHELF; SIZE NOT DISCLOSED - SEC FILING Source text: (https://bit.ly/2q8HM38) Further company coverage:
BRIEF-Epizyme Q4 Loss Per Share $0.52
* EPIZYME REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING RESULTS AND 2018 MILESTONES
Select another date:
- Your Daily Pharma Scoop: Epizyme Down, MiMedx Proceeds, Summit Beats
- Biotech Analysis Central Pharma News: Teva's U.S. Erosion, Denali's Preliminary Results, Epizyme's Trial Shutdown
- You Should Not Miss Epizyme In 2018
- Epizyme (EPZM) Tazemetostat Interim Phase 2 Data in Follicular Lymphoma - Slideshow
- Your Daily Pharma Scoop: Selecta Bio Reports Positive, Acceleron And Atara Moves Up On Positive Data
- Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold